Mounjaro commonly causes digestive side effects such as nausea, diarrhoea, decreased appetite, vomiting, constipation, indigestion and abdominal pain. These problems are particularly associated with starting treatment and increasing the dose, and they often become less troublesome over time.
Tirzepatide can also cause less common but more serious problems. Current prescribing information includes warnings about acute pancreatitis, gallbladder disease, dehydration and kidney injury, severe gastrointestinal reactions, serious allergic reactions and low blood sugar when Mounjaro is combined with certain diabetes medicines.
People with diabetic retinopathy also need appropriate monitoring. Rapid improvements in blood glucose can temporarily worsen diabetic retinopathy in some patients, although this is different from saying that Mounjaro itself is known to cause a specific new eye disease.
This guide separates the common effects of Mounjaro from the symptoms and risks that warrant closer medical attention.
Key points
- Nausea and diarrhoea are among the most frequently reported Mounjaro side effects.
- Digestive side effects are particularly common while the dose is being increased.
- Severe, persistent abdominal pain can be a warning sign of acute pancreatitis.
- Prolonged vomiting or diarrhoea can cause dehydration and contribute to kidney problems.
- Gallstones and inflammation of the gallbladder are recognised risks.
- The risk of hypoglycaemia is higher when Mounjaro is used with insulin or medicines that stimulate insulin release.
- People with a history of diabetic retinopathy should be monitored for changes in their condition.
Which Mounjaro side effects are most common?
Mounjaro contains tirzepatide, which acts on both GIP and GLP-1 receptors. Gastrointestinal problems account for many of the side effects reported during treatment.
In the placebo-controlled trials described in current US prescribing information, the following adverse reactions occurred in at least 5% of adults treated with Mounjaro:
| Side effect | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Nausea | 12% | 15% | 18% | 4% |
| Diarrhoea | 12% | 13% | 17% | 9% |
| Decreased appetite | 5% | 10% | 11% | 1% |
| Vomiting | 5% | 5% | 9% | 2% |
| Constipation | 6% | 6% | 7% | 1% |
| Dyspepsia | 8% | 8% | 5% | 3% |
| Abdominal pain | 6% | 5% | 5% | 4% |
Clinical-trial percentages describe what happened in the study populations. They cannot predict whether an individual patient will experience a particular side effect.
Why stomach problems are so common
Tirzepatide affects the gastrointestinal system and delays gastric emptying. Nausea, vomiting and diarrhoea are therefore well-recognised effects of treatment.
In pooled US placebo-controlled trials, gastrointestinal adverse reactions occurred in 37.1% of patients receiving 5 mg, 39.6% receiving 10 mg and 43.6% receiving 15 mg, compared with 20.4% receiving placebo.
Most reports of nausea, vomiting and diarrhoea occurred during tirzepatide dose escalation and decreased over time.
This does not mean severe or persistent symptoms should simply be endured. Current US prescribing information also warns that severe gastrointestinal reactions can occur, and Mounjaro is not recommended in patients with severe gastroparesis.
Do Mounjaro side effects get better?
They often do, particularly the gastrointestinal effects associated with dose escalation. The pattern is not the same for everyone, however.
In the US placebo-controlled trials, 3.0% of patients taking 5 mg, 5.4% taking 10 mg and 6.6% taking 15 mg discontinued treatment because of gastrointestinal adverse reactions, compared with 0.4% receiving placebo.
Symptoms that remain severe, interfere with eating or drinking, or continue without improvement should be discussed with the clinician managing treatment.
Mounjaro and pancreatitis
Acute pancreatitis has been reported in patients treated with tirzepatide. Current US and European prescribing information both include pancreatitis among the important risks associated with Mounjaro.
The characteristic warning symptom is persistent, severe abdominal pain. The pain can sometimes spread to the back and may occur with or without vomiting.
Someone experiencing symptoms suggestive of pancreatitis should seek prompt medical assessment rather than assuming the pain is an ordinary digestive side effect.
European product information states that Mounjaro should be discontinued if pancreatitis is suspected and should not be restarted if acute pancreatitis is confirmed. Elevated pancreatic enzymes on their own do not establish that a patient has pancreatitis.
Gallbladder problems
Mounjaro has also been associated with acute gallbladder disease, including gallstones and inflammation of the gallbladder.
Symptoms that can accompany a gallbladder problem include:
- persistent or severe upper abdominal pain;
- fever;
- yellowing of the skin or eyes; and
- pale or clay-coloured stools.
These symptoms need medical assessment because abdominal pain during Mounjaro treatment has several possible causes and cannot be diagnosed reliably from symptoms alone.
Dehydration and kidney problems
The connection between Mounjaro and kidney problems is often indirect. Significant nausea, vomiting or diarrhoea can cause dehydration and loss of electrolytes. This can in turn worsen kidney function and has been associated with acute kidney injury.
Current US information advises monitoring kidney function when adverse reactions could lead to volume depletion, particularly during treatment initiation and dose escalation.
People who cannot keep fluids down or who develop prolonged vomiting or diarrhoea should seek medical advice.
Does Mounjaro affect the eyes?
Current prescribing information does not establish a specific Mounjaro eye disorder as a common adverse effect. There is, however, an important issue for people who already have diabetic retinopathy.
Rapid improvement in blood glucose has long been associated with temporary worsening of diabetic retinopathy. Current US Mounjaro prescribing information says patients with a history of diabetic retinopathy should be monitored for progression.
Mounjaro has not been studied in certain patients with more advanced diabetic eye disease, including proliferative diabetic retinopathy and diabetic macular oedema.
This should not be confused with non-arteritic anterior ischaemic optic neuropathy (NAION). European regulators have classified NAION as a very rare side effect of semaglutide, the active ingredient in medicines including Ozempic and Wegovy. That regulatory finding does not currently apply to tirzepatide simply because both medicines are used in related areas of care.
Any sudden loss of vision or significant new change in eyesight warrants prompt medical assessment regardless of the suspected cause.
Low blood sugar depends partly on other medicines
Mounjaro lowers blood glucose, but the risk of clinically important hypoglycaemia is particularly relevant when tirzepatide is taken with insulin or an insulin secretagogue such as a sulfonylurea.
Symptoms can include sweating, shaking, hunger, dizziness, confusion, weakness, blurred vision or a fast heartbeat.
A clinician may reduce the dose of insulin or an insulin secretagogue when it is used alongside Mounjaro. Patients should not make these dose changes themselves unless instructed to do so.
Other serious reactions to know about
Severe allergic reactions
Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Mounjaro.
Swelling of the face, lips, tongue or throat, difficulty breathing or swallowing, or other symptoms of a severe allergic reaction require urgent medical care.
Thyroid C-cell tumour warning in the US
US prescribing information for Mounjaro carries a boxed warning about the risk of thyroid C-cell tumours.
Tirzepatide caused thyroid C-cell tumours in rats. It is not known whether Mounjaro causes thyroid C-cell tumours, including medullary thyroid carcinoma (MTC), in humans.
In the United States, Mounjaro is contraindicated in people with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Surgery and anaesthesia
Because Mounjaro delays gastric emptying, residual stomach contents may remain despite normal fasting before a procedure. Pulmonary aspiration has been reported in people receiving GLP-1-related medicines during general anaesthesia or deep sedation.
Patients should tell their surgical and anaesthesia teams that they use Mounjaro before a planned procedure. Decisions about temporarily changing treatment should be made by the healthcare professionals involved.
When a side effect needs medical attention
| Symptom | Why it matters |
|---|---|
| Severe, persistent abdominal pain, sometimes spreading to the back | Possible acute pancreatitis |
| Persistent vomiting or diarrhoea, especially with difficulty keeping fluids down | Risk of dehydration and kidney injury |
| Upper abdominal pain with fever or jaundice | Possible gallbladder disease |
| Swelling of the face, tongue or throat or difficulty breathing | Possible serious allergic reaction |
| Severe symptoms of low blood sugar | Particularly relevant with insulin or insulin-releasing medicines |
| Sudden or significant change in vision | Requires assessment to identify the cause |
This is not a complete list of possible medical problems. Severe, rapidly worsening or otherwise concerning symptoms should be assessed according to their seriousness rather than waiting for them to match a particular list.
Questions about Mounjaro side effects
What is the most common side effect of Mounjaro?
Nausea and diarrhoea are among the most frequently reported adverse reactions. In US placebo-controlled trials, nausea was reported in 12% to 18% of Mounjaro-treated patients depending on dose, while diarrhoea was reported in 12% to 17%.
Are Mounjaro side effects worse after increasing the dose?
Gastrointestinal symptoms are particularly associated with dose escalation. US trial data show that most nausea, vomiting and diarrhoea occurred while doses were being increased and decreased over time.
Can Mounjaro cause pancreatitis?
Acute pancreatitis has been reported with tirzepatide and is included in current US and European safety information. Severe, persistent abdominal pain requires prompt medical assessment.
Can Mounjaro cause eye problems?
People with diabetic retinopathy may need closer monitoring because rapid improvement in glucose control can temporarily worsen retinopathy. Current regulatory information does not establish NAION as a tirzepatide side effect; the European NAION finding concerns semaglutide medicines.
Can Mounjaro affect your kidneys?
Kidney injury can occur particularly when vomiting, diarrhoea or other gastrointestinal effects cause significant dehydration. Patients with prolonged symptoms or difficulty maintaining fluid intake should contact a healthcare professional.
Does Mounjaro cause low blood sugar?
The risk is particularly important when Mounjaro is combined with insulin or an insulin secretagogue such as a sulfonylurea. A clinician may need to adjust those medicines.
Should I stop Mounjaro because of side effects?
Not solely on the basis of general online information. Mild gastrointestinal effects may improve, while some symptoms require prompt or emergency assessment. Treatment changes should normally be discussed with the healthcare professional managing the prescription.
Related MediSearcher guides
- Mounjaro medication reference
- Ozempic vs Mounjaro comparison
- Wegovy vs Mounjaro comparison
- Mounjaro vs Zepbound comparison
- Tirzepatide dosing: Mounjaro and Zepbound dose guide
- Ozempic side effects
Reviewed by: Dr Mattias Hagman, PhD
Editorial review: MediSearcher checks medication safety guides against current regulatory and prescribing information and distinguishes between established adverse effects, warnings and risks that apply only in particular clinical circumstances.
Last reviewed: 29 October 2026
Sources and verification
This guide was checked against current US and European Mounjaro prescribing and regulatory information available on 29 October 2026. Medication safety information can change as new evidence is reviewed.
- US Mounjaro Prescribing Information — US Food and Drug Administration / Eli Lilly
- Mounjaro US Prescribing Information — Eli Lilly
- Mounjaro EPAR — European Medicines Agency
- Mounjaro Product Information — European Medicines Agency
This article is for general informational purposes and does not replace individual medical advice. Mounjaro is a prescription medicine. Questions about side effects, treatment suitability or changes to prescribed treatment should be discussed with an appropriate healthcare professional.